: There is still the need to lower LDL-c, although the use of statins, ezetimibe and proprotein convertase subtilisin/kexin type 9. Patients with atherosclerotic cardiovascular disease and/or familial hypercholesterolaemia are treated with statins at maximum tolerated dose, with or without further lipid-lowering drugs, but very often, we can't reach the goal, so bempedoic acid treatment lead to a significant reduction in low-density lipoprotein cholesterol, in different groups of patients, with a favourable safety profile.
Bempedoic acid. what prospective uses / Jacomelli, Ilaria; Monzo, Luca; Panattoni, Germana; Lanzillo, Chiara; Rebecchi, Marco; Calò, Leonardo. - In: EUROPEAN HEART JOURNAL SUPPLEMENTS. - ISSN 1554-2815. - 25:Suppl C(2023), pp. C109-C111. [10.1093/eurheartjsupp/suad012]
Bempedoic acid. what prospective uses
Monzo, Luca;
2023
Abstract
: There is still the need to lower LDL-c, although the use of statins, ezetimibe and proprotein convertase subtilisin/kexin type 9. Patients with atherosclerotic cardiovascular disease and/or familial hypercholesterolaemia are treated with statins at maximum tolerated dose, with or without further lipid-lowering drugs, but very often, we can't reach the goal, so bempedoic acid treatment lead to a significant reduction in low-density lipoprotein cholesterol, in different groups of patients, with a favourable safety profile.| File | Dimensione | Formato | |
|---|---|---|---|
|
Jacomello_Bempedoic _2023.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
158.11 kB
Formato
Adobe PDF
|
158.11 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
